Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIAD: High-Dose/Dual-Boosted Fosamprenavir in HIV
NCT00144833Phase 3Terminated
- Sponsor
- GSK
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of fosamprenavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by GSK. Started Mar 2005; status: terminated.
02
Drugs
fosamprenavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00144833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144833.